company background image
EGRX logo

Eagle Pharmaceuticals NasdaqGM:EGRX Stock Report

Last Price

US$5.01

Market Cap

US$65.1m

7D

-11.8%

1Y

-82.4%

Updated

27 Mar, 2024

Data

Company Financials

Eagle Pharmaceuticals, Inc.

NasdaqGM:EGRX Stock Report

Market Cap: US$65.1m

EGRX Stock Overview

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

EGRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance1/6
Financial Health4/6
Dividends0/6

Eagle Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eagle Pharmaceuticals
Historical stock prices
Current Share PriceUS$5.01
52 Week HighUS$32.44
52 Week LowUS$4.10
Beta0.43
1 Month Change-22.69%
3 Month Change-7.48%
1 Year Change-82.44%
3 Year Change-88.00%
5 Year Change-90.00%
Change since IPO-60.95%

Recent News & Updates

Recent updates

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Sep 21
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Jul 13
Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

Jun 21
Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Oct 12

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Sep 27

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Aug 18

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Aug 09

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Dec 16
Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Jul 06
Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package

Eagle Pharmaceuticals: A Potential Reopening Play

Jun 16

Eagle Pharmaceuticals EPS misses by $0.49, misses on revenue

May 10

Eagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphoma

Apr 30

Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt

Apr 15
Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price

Mar 25
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price

Shareholder Returns

EGRXUS BiotechsUS Market
7D-11.8%0.9%0.4%
1Y-82.4%10.3%28.8%

Return vs Industry: EGRX underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: EGRX underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is EGRX's price volatile compared to industry and market?
EGRX volatility
EGRX Average Weekly Movement10.8%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: EGRX's share price has been volatile over the past 3 months.

Volatility Over Time: EGRX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2007134Mike Graveshttps://www.eagleus.com

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.

Eagle Pharmaceuticals, Inc. Fundamentals Summary

How do Eagle Pharmaceuticals's earnings and revenue compare to its market cap?
EGRX fundamental statistics
Market capUS$65.06m
Earnings (TTM)US$11.95m
Revenue (TTM)US$257.55m

5.4x

P/E Ratio

0.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EGRX income statement (TTM)
RevenueUS$257.55m
Cost of RevenueUS$77.68m
Gross ProfitUS$179.88m
Other ExpensesUS$167.93m
EarningsUS$11.95m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.92
Gross Margin69.84%
Net Profit Margin4.64%
Debt/Equity Ratio27.8%

How did EGRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.